Abstract
Background
Diffuse intrinsic pontine glioma (DIPG) is a lethal type of pediatric brain tumor that is resistant to conventional chemotherapies. Palbociclib is a putative novel DIPG treatment that restricts the proliferation of rapidly dividing cancer cells via selective inhibition of cyclin-dependent kinase (CDK) 4 and CDK6. However, implementing palbociclib as a monotherapy for DIPG is unfeasible, as CDK4/6 inhibitor resistance is commonplace and palbociclib does not readily cross the blood–brain barrier (BBB) or persist in the central nervous system. To inhibit the growth of DIPG cells, we aimed to use palbociclib in combination with the rapamycin analog temsirolimus, which is known to ameliorate resistance to CDK4/6 inhibitors and inhibit BBB efflux.
Materials and methods
We tested palbociclib and temsirolimus in three patient-derived DIPG cell lines. The expression profiles of key proteins in the CDK4/6 and mammalian target of rapamycin (mTOR) signaling pathways were assessed, respectively, to determine feasibility against DIPG. Moreover, we investigated effects on cell viability and examined in vivo drug toxicity.
Results
Immunoblot analyses revealed palbociclib and temsirolimus inhibited CDK4/6 and mTOR signaling through canonical perturbation of phosphorylation of the retinoblastoma (RB) and mTOR proteins, respectively; however, we observed noncanonical downregulation of mTOR by palbociclib. We demonstrated that palbociclib and temsirolimus inhibited cell proliferation in all three DIPG cell lines, acting synergistically in combination to further restrict cell growth. Flow cytometric analyses revealed both drugs caused G1 cell cycle arrest, and clonogenic assays showed irreversible effects on cell proliferation. Palbociclib did not elicit neurotoxicity in primary cultures of normal rat hippocampi or when infused into rat brains.
Conclusion
These data illustrate the in vitro antiproliferative effects of CDK4/6 and mTOR inhibitors in DIPG cells. Direct infusion of palbociclib into the brain, in combination with systemic delivery of temsirolimus, represents a promising new approach to developing a much-needed treatment for DIPG.
Acknowledgments
The authors thank Abbie’s Army DIPG brain tumor research charity for their generous financial support. The authors also thank Dr Nalin Gupta for the SF7761 and SF8628 cell lines, Dr Michelle Monje for the SU-DIPG IV cell line, and Dr Alex Hoose for general advice and assistance. This study was funded by Abbie’s Army DIPG brain tumor research charity (to NU Barua and AS Bienemann), the Functional Neurosurgery Research Fund held by Southmead Hospital Charities (SS Gill), the Gatsby foundation (to WGB Singleton), and joint funding from the Medical Research Council and the Brain Tumour Charity (grant no. MR/N00130/1 to WGB Singleton).
Disclosure
SS Gill is a consultant for Renishaw PLC. NU Barua is a consultant for Renishaw PLC. The authors report no other conflicts of interest in this work.